A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Luis E. Raez, Kyriakos Papadopoulos, Alejandro D. Ricart, E. Gabriella Chiorean, Robert S. Dipaola, Mark N. Stein, Caio M. Rocha Lima, James J. Schlesselman, Khaled Tolba, Virginia K. Langmuir, Stewart Kroll, Donald T. Jung, Metin Kurtoglu, Joseph D Rosenblatt, Theodore Lampidis

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Purpose: This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. Methods: A modified accelerated titration design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered intravenously at 30 mg/m2 for 3 of every 4 weeks beginning on day 1 of week 2. Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-week cycle for up to 12 cycles. Results: Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule. There were no dose-limiting toxicities which met the MTD criteria. The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration. Therefore, 63 mg/kg was selected as the clinically tolerable dose. The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 %), gastrointestinal bleeding (6 %) and reversible grade 3 QTc prolongation (22 %). Eleven patients (32 %) had stable disease, 1 patient (3 %) partial response and 22 patients (66 %) progressive disease as their best response. There was no PK interaction between 2DG and docetaxel. Conclusion: The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects.

Original languageEnglish
Pages (from-to)523-530
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume71
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

docetaxel
Tumors
Glucose
Neoplasms
Pharmacokinetics
Maximum Tolerated Dose
Sweating
Dizziness
Titration
Hypoglycemic Agents
Hyperglycemia
Nausea
Fatigue
Toxicity
Appointments and Schedules

Keywords

  • 2-Deoxy-d-Glucose
  • Breast cancer
  • Docetaxel
  • Head and neck cancers
  • Lung cancer
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. / Raez, Luis E.; Papadopoulos, Kyriakos; Ricart, Alejandro D.; Chiorean, E. Gabriella; Dipaola, Robert S.; Stein, Mark N.; Rocha Lima, Caio M.; Schlesselman, James J.; Tolba, Khaled; Langmuir, Virginia K.; Kroll, Stewart; Jung, Donald T.; Kurtoglu, Metin; Rosenblatt, Joseph D; Lampidis, Theodore.

In: Cancer Chemotherapy and Pharmacology, Vol. 71, No. 2, 01.02.2013, p. 523-530.

Research output: Contribution to journalArticle

Raez, LE, Papadopoulos, K, Ricart, AD, Chiorean, EG, Dipaola, RS, Stein, MN, Rocha Lima, CM, Schlesselman, JJ, Tolba, K, Langmuir, VK, Kroll, S, Jung, DT, Kurtoglu, M, Rosenblatt, JD & Lampidis, T 2013, 'A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors', Cancer Chemotherapy and Pharmacology, vol. 71, no. 2, pp. 523-530. https://doi.org/10.1007/s00280-012-2045-1
Raez, Luis E. ; Papadopoulos, Kyriakos ; Ricart, Alejandro D. ; Chiorean, E. Gabriella ; Dipaola, Robert S. ; Stein, Mark N. ; Rocha Lima, Caio M. ; Schlesselman, James J. ; Tolba, Khaled ; Langmuir, Virginia K. ; Kroll, Stewart ; Jung, Donald T. ; Kurtoglu, Metin ; Rosenblatt, Joseph D ; Lampidis, Theodore. / A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. In: Cancer Chemotherapy and Pharmacology. 2013 ; Vol. 71, No. 2. pp. 523-530.
@article{8b5d9c9ac8e54596b10ecb6ee43875bc,
title = "A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors",
abstract = "Purpose: This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. Methods: A modified accelerated titration design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered intravenously at 30 mg/m2 for 3 of every 4 weeks beginning on day 1 of week 2. Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-week cycle for up to 12 cycles. Results: Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule. There were no dose-limiting toxicities which met the MTD criteria. The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration. Therefore, 63 mg/kg was selected as the clinically tolerable dose. The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 {\%}), gastrointestinal bleeding (6 {\%}) and reversible grade 3 QTc prolongation (22 {\%}). Eleven patients (32 {\%}) had stable disease, 1 patient (3 {\%}) partial response and 22 patients (66 {\%}) progressive disease as their best response. There was no PK interaction between 2DG and docetaxel. Conclusion: The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects.",
keywords = "2-Deoxy-d-Glucose, Breast cancer, Docetaxel, Head and neck cancers, Lung cancer, Phase I",
author = "Raez, {Luis E.} and Kyriakos Papadopoulos and Ricart, {Alejandro D.} and Chiorean, {E. Gabriella} and Dipaola, {Robert S.} and Stein, {Mark N.} and {Rocha Lima}, {Caio M.} and Schlesselman, {James J.} and Khaled Tolba and Langmuir, {Virginia K.} and Stewart Kroll and Jung, {Donald T.} and Metin Kurtoglu and Rosenblatt, {Joseph D} and Theodore Lampidis",
year = "2013",
month = "2",
day = "1",
doi = "10.1007/s00280-012-2045-1",
language = "English",
volume = "71",
pages = "523--530",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

AU - Raez, Luis E.

AU - Papadopoulos, Kyriakos

AU - Ricart, Alejandro D.

AU - Chiorean, E. Gabriella

AU - Dipaola, Robert S.

AU - Stein, Mark N.

AU - Rocha Lima, Caio M.

AU - Schlesselman, James J.

AU - Tolba, Khaled

AU - Langmuir, Virginia K.

AU - Kroll, Stewart

AU - Jung, Donald T.

AU - Kurtoglu, Metin

AU - Rosenblatt, Joseph D

AU - Lampidis, Theodore

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Purpose: This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. Methods: A modified accelerated titration design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered intravenously at 30 mg/m2 for 3 of every 4 weeks beginning on day 1 of week 2. Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-week cycle for up to 12 cycles. Results: Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule. There were no dose-limiting toxicities which met the MTD criteria. The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration. Therefore, 63 mg/kg was selected as the clinically tolerable dose. The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 %), gastrointestinal bleeding (6 %) and reversible grade 3 QTc prolongation (22 %). Eleven patients (32 %) had stable disease, 1 patient (3 %) partial response and 22 patients (66 %) progressive disease as their best response. There was no PK interaction between 2DG and docetaxel. Conclusion: The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects.

AB - Purpose: This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. Methods: A modified accelerated titration design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered intravenously at 30 mg/m2 for 3 of every 4 weeks beginning on day 1 of week 2. Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-week cycle for up to 12 cycles. Results: Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule. There were no dose-limiting toxicities which met the MTD criteria. The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration. Therefore, 63 mg/kg was selected as the clinically tolerable dose. The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 %), gastrointestinal bleeding (6 %) and reversible grade 3 QTc prolongation (22 %). Eleven patients (32 %) had stable disease, 1 patient (3 %) partial response and 22 patients (66 %) progressive disease as their best response. There was no PK interaction between 2DG and docetaxel. Conclusion: The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects.

KW - 2-Deoxy-d-Glucose

KW - Breast cancer

KW - Docetaxel

KW - Head and neck cancers

KW - Lung cancer

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=84874116164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874116164&partnerID=8YFLogxK

U2 - 10.1007/s00280-012-2045-1

DO - 10.1007/s00280-012-2045-1

M3 - Article

VL - 71

SP - 523

EP - 530

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -